As on Thursday, Kura Oncology Inc (NASDAQ: KURA) started slowly as it slid -2.54% to $8.82, before settling in for the price of $9.05 at the close. Taking a more long-term approach, KURA posted a 52-week range of $6.98-$24.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 0.00% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -3.94%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -17.81%. This publicly-traded company’s shares outstanding now amounts to $77.75 million, simultaneously with a float of $65.24 million. The organization now has a market capitalization sitting at $685.87 million. At the time of writing, stock’s 50-day Moving Average stood at $9.01, while the 200-day Moving Average is $17.04.
Kura Oncology Inc (KURA) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Kura Oncology Inc’s current insider ownership accounts for 16.10%, in contrast to 97.63% institutional ownership. According to the most recent insider trade that took place on Jan 28 ’25, this organization’s SVP, Finance & Accounting sold 4,949 shares at the rate of 7.87, making the entire transaction reach 38,958 in total value, affecting insider ownership by 88,193. Preceding that transaction, on Jan 28 ’25, Company’s Chief Medical Officer sold 4,963 for 7.87, making the whole transaction’s value amount to 39,068. This particular insider is now the holder of 88,253 in total.
Kura Oncology Inc (KURA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.65 per share during the current fiscal year.
Kura Oncology Inc’s EPS decrease for this current 12-month fiscal period is -17.81% and is forecasted to reach -1.83 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 2.42% through the next 5 years, which can be compared against the -3.94% growth it accomplished over the previous five years trading on the market.
Kura Oncology Inc (NASDAQ: KURA) Trading Performance Indicators
Let’s observe the current performance indicators for Kura Oncology Inc (KURA). It’s Quick Ratio in the last reported quarter now stands at 11.47. The Stock has managed to achieve an average true range (ATR) of 0.56.
In the same vein, KURA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.36, a figure that is expected to reach -0.64 in the next quarter, and analysts are predicting that it will be -1.83 at the market close of one year from today.
Technical Analysis of Kura Oncology Inc (KURA)
Through scrutinizing the latest numbers posted by the [Kura Oncology Inc, KURA], it can be observed that its last 5-days Average volume of 3.63 million was better the volume of 1.94 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 90.37% While, its Average True Range was 0.61.
Raw Stochastic average of Kura Oncology Inc (KURA) in the period of the previous 100 days is set at 12.76%, which indicates a major fall in contrast to 83.17% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 50.87% that was lower than 84.24% volatility it exhibited in the past 100-days period.
